KYMR Q3 2024 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-20.9% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$72M-1927.9% margin

Net Income

-$62M-1670.3% margin

EPS (Diluted)

$-0.82

QoQ Revenue Growth

-85.4%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$50M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$142M

Stockholders' Equity

$893M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-20.9%
Gross Profit	$4M	$5M	-20.9%
Operating Income	-$72M	-$58M	-25.4%
Net Income	-$62M	-$53M	-18.2%